drugset / Trial / NCT00275301
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
NaSingle-groupOpen-labelTreatment
Summary
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-04
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 7.5 mg | Oral |